云顶新耀(1952.HK):商业化拐点,耐赋康销售峰值剑指50亿元

向阳论医谈药
07 Jun

Hi~新朋友,记得点蓝字关注我们哟投资要点推荐逻辑:1)耐赋康是中国首个且唯一获批的IgA肾病治疗药物,上市后放量明显,销售峰值剑指50亿元;2)伊曲莫德为新一代口服治疗溃疡性结肠炎药物,有望于2025年底前获批上市;3)EVER001为共价可逆BTK抑制剂,潜在同类最佳产品,授权潜力大。耐赋康是中国首个且唯一获批的IgA肾病治疗药物,销售峰值剑指50亿元。耐赋康于2023年11月获国家药监局批准...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10